* Please be kindly noted that our services and products can only be used for research by organizations or companies and are not intended for clinical or individual use.
BOC Sciences provides end-to-end ATTEC degradation technology development services for research teams exploring autophagy-based targeted degradation. ATTEC, short for Autophagosome-Tethering Compound, is a degrader modality that brings a target of interest into proximity with LC3 and the autophagy-lysosome system to promote selective clearance. Our support spans target feasibility analysis, LC3-oriented design strategy, degrader synthesis, mechanistic validation, cell-based activity assessment, and iterative optimization. Whether your project focuses on aggregation-prone proteins, difficult intracellular targets, or non-protein pathogenic substrates, we help transform early concepts into experimentally validated ATTEC candidates with clear development direction.
Compared with ubiquitin-proteasome-dependent degraders such as PROTACs and molecular glues, ATTEC follows a distinct degradation logic centered on autophagy rather than E3 ligase recruitment. This gives ATTEC unique potential for targets such as protein aggregates, challenging intracellular substrates, and certain non-protein pathogenic materials, while also demanding stronger attention to autophagy biology, credible LC3 engagement hypotheses, careful pathway validation, and target-specific assay design. From early target review through focused design and screening, our team builds practical research workflows that reduce uncertainty, improve decision quality, and accelerate the transition from exploratory ideas to robust degrader leads.
Services
BOC Sciences' Comprehensive ATTEC Development Services
Target Feasibility and Autophagy Suitability Assessment
We begin by determining whether ATTEC is scientifically appropriate for your target and project objective. This includes reviewing target biology, aggregation behavior, intracellular localization, turnover features, disease relevance, and the likelihood that autophagy-based clearance can generate a measurable research outcome.
Target biology and disease-mechanism review
Autophagy compatibility and degradation-pathway assessment
Early-stage risk identification and route selection
LC3-Oriented ATTEC Molecular Design
Because ATTEC discovery depends on productive target tethering to autophagy machinery, we design candidates by integrating target ligand information, LC3-binding strategy, linker architecture, and subcellular context. We support both de novo design and redesign of existing ligands into autophagy-tethering formats.
LC3-binding warhead selection strategy
Target ligand adaptation and attachment-point analysis
For exploratory programs, we help clients build efficient screening workflows to identify tractable ATTEC starting points. Depending on project maturity, this may involve focused library design, target-oriented compound triage, or mechanism-informed screening cascades that prioritize meaningful degraders over false positives.
Hit triage based on degradation phenotype and pathway relevance
Negative-control and orthogonal-validation strategy
ATTEC Synthesis and Chemistry Optimization
We provide synthetic chemistry support from initial ATTEC preparation to focused analog expansion. By iterating on target binder, LC3-binding element, linker length, rigidity, polarity, and exit vectors, we help improve degradation efficiency, cellular activity, and research usability.
Hit and lead compound synthesis
Focused analog series generation
Structure-activity and structure-property analysis
Chemistry optimization for permeability and stability balance
Mechanism Confirmation and Cell-Based Degradation Evaluation
ATTEC projects require more than observing target loss. We establish mechanism-focused evaluation workflows to verify whether target reduction is associated with autophagy-lysosome engagement, LC3-dependent tethering logic, and meaningful downstream cellular effects.
Integrated Discovery Workflow for Alternative Degrader Programs
If your project needs comparative strategy evaluation, we can position ATTEC alongside other degrader modalities and help select the most practical route based on target class, biology, assay tractability, and research goals. This is particularly valuable when proteasomal degradation is insufficient or when lysosome-mediated clearance may offer unique advantages.
Our Solutions for Key ATTEC Development Bottlenecks
BOC Sciences designs ATTEC projects around the scientific decisions that most often determine success: target selection, LC3-recruitment logic, mechanistic confidence, and iterative chemistry-biology learning.
Solution for Choosing the Right Target and Degradation Route
Not every target benefits equally from ATTEC design. We assess target form, intracellular context, known ligandability, autophagy relevance, and measurable cellular phenotype to determine when ATTEC is likely to be a high-value strategy and when other degrader modalities may be more suitable.
Solution for LC3 Recruitment and Molecule Architecture
ATTEC design is highly sensitive to molecular geometry and tethering logic. We optimize LC3-oriented design hypotheses, target-ligand adaptation, linker composition, and attachment positions to improve the chance of productive autophagosome recruitment and robust degradation behavior.
Solution for Mechanistic Validation
We build assay cascades that go beyond simple target depletion. By combining target-level readouts, lysosome/autophagy intervention studies, cellular imaging, and orthogonal controls, we help clients determine whether a candidate behaves as a genuine ATTEC rather than a nonspecific stress-inducing compound.
Solution for Lead Advancement and Research Usability
Early ATTEC hits often need extensive optimization to improve permeability, exposure, and reproducibility. We integrate chemistry refinement with cell-based evidence generation so that clients receive not only compounds, but also the decision-enabling data needed to prioritize the next round of discovery.
Build ATTEC programs with stronger mechanistic confidence and clearer optimization logic.
From target review to validated degrader candidates, BOC Sciences provides flexible, science-driven support for autophagy-based targeted degradation programs across discovery stages.
Our ATTEC Solutions Support Diverse Research and Drug Discovery Teams
Academic Laboratories and Disease Biology Groups
For teams studying protein aggregation, autophagy biology, or new degradation hypotheses, we provide practical support for target evaluation, probe design, synthesis, and mechanistic assays that can accelerate high-quality data generation and research progression.
Biotechnology Companies
Emerging biotech programs often need fast answers on feasibility, hit quality, and next-step prioritization. Our modular ATTEC services help shorten exploratory cycles and provide decision-ready data for internal portfolio advancement.
Pharmaceutical Discovery Teams
For organizations investigating targets outside the effective scope of conventional inhibitors or classical degraders, we provide ATTEC strategy development, comparative degrader assessment, and chemistry-biology execution to open new research directions.
CROs and Technical Service Partners
When autophagy-based degradation sits outside existing in-house capabilities, we offer specialized ATTEC modules that strengthen client delivery across design, synthesis, and mechanism-focused evaluation.
We align on target class, available ligands, disease context, intended degradation objective, and key scientific questions.
02
Feasibility Analysis and Route Definition
Our team evaluates target suitability for autophagy-mediated degradation and defines whether ATTEC is the preferred discovery route.
03
Design Strategy and Proposal Finalization
We propose a research plan covering molecular design logic, screening sequence, deliverables, and optimization milestones.
04
Candidate Design and Synthesis
We generate ATTEC candidates through target-ligand adaptation, LC3-oriented design, linker engineering, and focused synthetic execution.
05
Primary Cell-Based Activity Screening
Initial compounds are evaluated for target reduction, concentration dependence, cellular tolerability, and reproducibility across relevant models.
06
Mechanistic Validation
We investigate autophagy-lysosome dependence, verify pathway consistency, and rule out misleading non-specific effects.
07
Multi-Parameter Optimization
Based on activity and property data, we optimize molecular architecture to improve degradation efficiency, selectivity, and research utility.
08
Data Delivery and Next-Stage Recommendation
Clients receive compounds, study data, interpretation, and practical recommendations for advancing, redirecting, or expanding the program.
Advantages
Why ATTEC Is an Important Modality in Targeted Degradation Research?
Expands Access Beyond Proteasomal Scope
ATTEC offers a lysosome-oriented degradation route that can be valuable for targets that are difficult to address through ubiquitin-proteasome-dependent strategies.
Supports Aggregate and Complex Cargo Research
The modality is particularly attractive for studying aggregation-prone proteins and other substrates for which autophagy-based clearance may be biologically meaningful.
Creates Opportunities for Non-Protein Targeting Concepts
ATTEC-inspired strategies have broadened degrader thinking beyond proteins, opening research possibilities for organelles and other pathogenic biomolecular structures.
Complements Other Degrader Platforms
Rather than replacing all other modalities, ATTEC adds a differentiated option that can be compared with PROTAC development strategies or other proximity-based degraders during target selection.
Applications
Research Areas Supported by Our ATTEC Development Services
Neurodegeneration and Protein Aggregation Research
Mutant huntingtin and related aggregate-prone targets
Tau and synuclein-associated research hypotheses
Intracellular pathogenic protein clearance studies
Client Success Stories: ATTEC Degradation Technology Development
Project Background
A research institution focused on neurodegenerative diseases sought to develop a therapeutic lead for Huntington's Disease. The target, mutant Huntingtin (mHTT) protein, forms large intracellular aggregates that are inaccessible to the proteasome-based PROTAC system. The client required a specialized ATTEC molecule capable of tethering these protein aggregates directly to the autophagosome protein LC3, facilitating their engulfment and subsequent lysosomal degradation without affecting the wild-type HTT protein.
Our Support
To meet this challenge, we leveraged our fragment-based drug discovery (FBDD) platform to identify small molecules that bind to the hydrophobic pockets of LC3 in its lipidated form (LC3-II). We then conjugated these LC3-binders with mHTT-selective warheads identified through virtual screening of expanded chemical libraries. During optimization, we focused on the linker's rigid-flexible balance to ensure the "tether" could bridge the bulky aggregate and the autophagosomal membrane effectively. We validated the mechanism using a dual-fluorescence (mCherry-GFP) mHTT reporter system and confirmed that the lead ATTEC compounds significantly reduced mHTT levels in a dose-dependent manner. Our results demonstrated a high degree of selectivity, sparing the physiological functions of normal HTT proteins while clearing pathogenic aggregates.
Client Testimonial
The BOC Sciences team provided a sophisticated solution for our aggregate-clearing project. Their expertise in LC3-binding motifs and the meticulous design of bifunctional tethers allowed us to achieve selective degradation of mHTT, opening a new avenue for our neurodegenerative disease pipeline.
Project Background
An innovative drug discovery company aimed to explore the degradation of non-protein targets, specifically lipid droplets (LDs) involved in metabolic disorders. Traditional degradation technologies are largely limited to proteins, leaving lipid-based organelles "undruggable." The client needed an ATTEC-based approach (LD-ATTEC) that could selectively recruit LC3 to the surface of lipid droplets to induce "lipophagy," thereby reducing lipid accumulation in specialized hepatic cell models.
Our Support
We designed a unique series of LD-ATTECs by linking an LC3-targeting ligand to a hydrophobic lipid-binding moiety with high affinity for the LD phospholipid monolayer. A critical difficulty was ensuring the molecule did not sequester in the plasma membrane. We addressed this by optimizing the LogP values and introducing specific structural motifs that prioritize LD localization. Through BODIPY staining and TEM (Transmission Electron Microscopy) analysis, we confirmed the recruitment of autophagosomes to the lipid droplets. The final optimized candidates showed a significant reduction in intracellular triglyceride levels and lipid droplet volume. This project successfully expanded the client's technological capability from protein degradation to organelle-level clearance.
Client Testimonial
BOC Sciences has been a vital partner in our exploration of lipophagy-inducing compounds. Their creative approach to molecular design and robust analytical validation enabled us to realize the first-in-class degradation of lipid droplets, proving the versatility of their ATTEC platform for non-traditional targets.
Why Choose Us
Why Choose BOC Sciences for Your ATTEC Development Project?
ATTEC-Focused Scientific Understanding
We understand the distinctive biology, design logic, and validation needs of autophagy-tethering compounds rather than treating them as simple variants of classical degraders.
Integrated Chemistry and Mechanism Support
Our workflows connect molecule design and synthesis with mechanism-sensitive biological evaluation, enabling faster learning between chemistry and cell data.
Practical Internal Linking to Wider TPD Capabilities
When useful, ATTEC projects can be supported by complementary resources such as degrader mechanism analysis and broader targeted degradation know-how.
Flexible Support for Early Discovery Programs
We can support individual tasks or integrated programs, from feasibility review and hit design to lead optimization and data interpretation.
Decision-Oriented Data Delivery
Our goal is not only to generate compounds, but also to provide the evidence clients need to decide whether to advance, refine, or redirect a program.
Strong Fit for Emerging Degrader Modalities
ATTEC sits within a broader innovation landscape of lysosome- and proximity-based degraders, and we help clients navigate that complexity with target-specific development logic.
ATTEC Degradation Technology is a targeted protein degradation strategy that leverages the autophagy-lysosome system to remove disease-associated proteins from cells. It typically uses small molecules or functional molecules to bring a target protein into proximity with autophagy-related components, enabling selective recognition, encapsulation, and degradation. Unlike conventional small-molecule inhibitors that mainly block protein activity, ATTEC focuses on eliminating the target protein itself, making it a valuable approach for drug discovery programs involving difficult-to-inhibit proteins, abnormal protein aggregation, and emerging targeted degradation research.
How Does ATTEC Degradation Technology Work?
ATTEC degradation technology works by promoting the association between a target protein and autophagy-related machinery, allowing the target to be delivered to the autophagy-lysosome pathway for degradation. Key development steps often include target protein recognition, ATTEC molecule design, structural optimization, autophagy recruitment assessment, and cell-based degradation evaluation. For drug discovery teams, this mechanism can open new opportunities beyond traditional inhibition-based approaches and support the exploration of molecular strategies designed to remove disease-relevant proteins rather than simply modulate their activity.
How Is ATTEC Different from PROTAC?
ATTEC and PROTAC are both targeted protein degradation approaches, but they rely on different cellular degradation systems. PROTACs usually recruit an E3 ligase to direct target proteins to the ubiquitin-proteasome system, while ATTEC primarily uses the autophagy-lysosome pathway. This distinction may make ATTEC particularly useful for exploring protein aggregates, larger protein complexes, or targets that are less suitable for proteasomal degradation. BOC Sciences can support early-stage evaluation and molecular design for different degradation strategies, including ATTEC and PROTAC, based on the target profile and project objectives.
What Drug Discovery Projects Fit ATTEC?
ATTEC is well suited for drug discovery projects that aim to remove target proteins through autophagy-mediated degradation, especially projects involving abnormal protein aggregates, pathogenic protein conformations, difficult-to-drug targets, or proteins associated with disrupted cellular homeostasis. At the early research stage, developers often need to assess whether a target is suitable for autophagy-based degradation, whether appropriate binding ligands are available, and how to establish reliable degradation assays. BOC Sciences provides target analysis, custom compound synthesis, structural modification, and in vitro evaluation support to help clients advance ATTEC discovery programs.
How to Choose ATTEC Development Services?
When selecting ATTEC development services, pharmaceutical and biotech teams often look for a partner with experience in targeted protein degradation, custom synthesis capabilities, medicinal chemistry support, and cell-based validation expertise. A successful ATTEC program requires more than compound synthesis; it also depends on target biology, rational molecular design, structure optimization, and degradation activity assessment. As a drug development service provider, BOC Sciences can support ATTEC molecule design, synthesis, optimization, and early discovery studies according to each client’s target protein, research goals, and project stage.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Expands Access Beyond Proteasomal Scope
